Literature DB >> 34956492

Microscale thermophoresis analysis of the molecular interaction between small nuclear ribonucleoprotein polypeptide G and the RING finger domain of RBBP6 towards anti-cancer drug discovery.

Lloyd Mabonga1, Priscilla Masamba2, Albertus Kotze Basson1, Abidemi Paul Kappo2.   

Abstract

Regulatory core-splicing proteins are now becoming highly promising therapeutic targets for the development of anti-cancer drugs. SNRPG and RBBP6 are two good examples of regulatory core-splicing proteins involved in tumorigenesis and tumor development whose multi-functional role is primarily mediated by protein-protein interactions. Over the years, skepticism abutting from the two onco-proteins has been mounting. Suggestive evidence using yeast 2-hybrid technique observed possible involvement between SNRPG and the RING finger domain of RBBP6. However, the putative interaction remains elusive and yet to be characterized. In this study, we developed the first MST-based assay to confirm the interaction between SNRPG and the RING finger domain of RBBP6. The results demonstrated a strong binding affinity between SNRPG and the RING finger domain of RBBP6 with a KD in the low nanomolar concentration range of 3.1596 nM. The results are congruent with previous findings suggesting possible involvement between the two proteins in cancer-cell networks, thereby providing a new mechanistic insight into the interaction between SNRPG and the RING finger domain of RBBP6. The interaction is therapeutically relevant and represents a great milestone in the anti-cancer drug discovery space. Identification of small molecule inhibitors to modulate the binding affinity between the two proteins would therefore be a major breakthrough in the development of new PPI-focused anti-cancer drugs. AJTR
Copyright © 2021.

Entities:  

Keywords:  Anti-cancer drug discovery; RBBP6; RING finger; SNPRG; cancer; microscale thermophoresis

Year:  2021        PMID: 34956492      PMCID: PMC8661184     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  53 in total

Review 1.  Protein-protein interactions: methods for detection and analysis.

Authors:  E M Phizicky; S Fields
Journal:  Microbiol Rev       Date:  1995-03

Review 2.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

3.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

4.  Cluster analysis of networks generated through homology: automatic identification of important protein communities involved in cancer metastasis.

Authors:  Pall F Jonsson; Tamara Cavanna; Daniel Zicha; Paul A Bates
Journal:  BMC Bioinformatics       Date:  2006-01-06       Impact factor: 3.169

5.  The Drosophila retinoblastoma binding protein 6 family member has two isoforms and is potentially involved in embryonic patterning.

Authors:  Rodney Hull; Brent Oosthuysen; Umar-Faruq Cajee; Lehlogonolo Mokgohloa; Ekene Nweke; Ricardo Jorge Antunes; Theresa H T Coetzer; Monde Ntwasa
Journal:  Int J Mol Sci       Date:  2015-05-06       Impact factor: 5.923

6.  Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification.

Authors:  C Heneghan; C Blacklock; R Perera; R Davis; A Banerjee; P Gill; S Liew; L Chamas; J Hernandez; K Mahtani; G Hayward; S Harrison; D Lasserson; S Mickan; C Sellers; D Carnes; K Homer; L Steed; J Ross; N Denny; C Goyder; M Thompson; A Ward
Journal:  BMJ Open       Date:  2013-07-06       Impact factor: 2.692

7.  Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial.

Authors:  Kiminori Kimura; Akemi Ikoma; Maki Shibakawa; Shinji Shimoda; Kenichi Harada; Masanao Saio; Jun Imamura; Yosuke Osawa; Masamichi Kimura; Koji Nishikawa; Takuji Okusaka; Satoshi Morita; Kazuaki Inoue; Tatsuya Kanto; Koji Todaka; Yoichi Nakanishi; Michinori Kohara; Masashi Mizokami
Journal:  EBioMedicine       Date:  2017-08-19       Impact factor: 8.143

Review 8.  An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice.

Authors:  Mohammed Saji Salahudeen; Prasad S Nishtala
Journal:  Saudi Pharm J       Date:  2016-07-09       Impact factor: 4.330

9.  The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.

Authors:  A C West; B P Martin; D A Andrews; S J Hogg; A Banerjee; G Grigoriadis; R W Johnstone; J Shortt
Journal:  Oncogenesis       Date:  2016-04-04       Impact factor: 7.485

10.  Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.

Authors:  Viktor Arnhold; Karin Schmelz; Jutta Proba; Annika Winkler; Jasmin Wünschel; Joern Toedling; Hedwig E Deubzer; Annette Künkele; Angelika Eggert; Johannes H Schulte; Patrick Hundsdoerfer
Journal:  Oncotarget       Date:  2017-12-18
View more
  1 in total

1.  Molecular interaction between small nuclear ribonucleoprotein polypeptide G and heat shock protein 70.14: a microscale thermophoresis exposition towards developing anti-cancer drugs.

Authors:  Lloyd Mabonga; Paul Chukwudi Ikwegbue; Priscilla Masamba; Abidemi Paul Kappo
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.